Adial Pharmaceuticals (ADIL) Competitors $0.33 0.00 (-1.24%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$0.32 -0.01 (-1.53%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL vs. IBIO, MTVA, LPTX, NERV, ACXP, ATHA, TRIB, BGXX, PHIO, and EQShould you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include iBio (IBIO), MetaVia (MTVA), Leap Therapeutics (LPTX), Minerva Neurosciences (NERV), Acurx Pharmaceuticals (ACXP), Athira Pharma (ATHA), Trinity Biotech (TRIB), Bright Green (BGXX), Phio Pharmaceuticals (PHIO), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry. Adial Pharmaceuticals vs. Its Competitors iBio MetaVia Leap Therapeutics Minerva Neurosciences Acurx Pharmaceuticals Athira Pharma Trinity Biotech Bright Green Phio Pharmaceuticals Equillium iBio (NYSE:IBIO) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends. Which has preferable valuation and earnings, IBIO or ADIL? Adial Pharmaceuticals has lower revenue, but higher earnings than iBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiBio$375K32.07-$24.91MN/AN/AAdial PharmaceuticalsN/AN/A-$13.20M-$1.46-0.22 Does the media prefer IBIO or ADIL? In the previous week, Adial Pharmaceuticals had 1 more articles in the media than iBio. MarketBeat recorded 2 mentions for Adial Pharmaceuticals and 1 mentions for iBio. iBio's average media sentiment score of 0.59 beat Adial Pharmaceuticals' score of 0.00 indicating that iBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is IBIO or ADIL more profitable? iBio's return on equity of -73.15% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets iBioN/A -73.15% -45.51% Adial Pharmaceuticals N/A -218.88%-177.61% Do insiders and institutionals hold more shares of IBIO or ADIL? 7.9% of iBio shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 0.6% of iBio shares are owned by insiders. Comparatively, 4.3% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, IBIO or ADIL? iBio has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Do analysts rate IBIO or ADIL? iBio currently has a consensus price target of $4.30, suggesting a potential upside of 490.66%. Adial Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 2,353.99%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than iBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iBio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Adial Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryAdial Pharmaceuticals beats iBio on 8 of the 13 factors compared between the two stocks. Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition Export to ExcelMetricAdial PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.41M$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-0.227.9419.5920.21Price / SalesN/A281.76418.25119.02Price / CashN/A42.7336.8958.10Price / Book0.517.518.035.67Net Income-$13.20M-$55.14M$3.18B$249.21M7 Day Performance-2.72%4.61%2.93%3.28%1 Month Performance-50.47%4.72%3.75%5.55%1 Year Performance-68.65%5.92%35.20%21.09% Adial Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals2.37 of 5 stars$0.33-1.2%$8.00+2,354.0%-68.8%$3.41MN/A-0.2220Gap DownIBIOiBio2.108 of 5 stars$0.76+1.1%$4.30+463.5%-63.0%$12.61M$375K0.00100MTVAMetaViaN/A$0.64+2.1%$7.50+1,066.0%N/A$12.60MN/A0.008Gap DownLPTXLeap Therapeutics1.424 of 5 stars$0.30+13.5%$3.38+1,036.7%-84.3%$12.30MN/A-0.1740News CoverageNERVMinerva Neurosciences3.1716 of 5 stars$1.72-3.4%$5.00+190.7%-45.9%$12.02MN/A2.109Gap DownACXPAcurx Pharmaceuticals2.6058 of 5 stars$0.51+18.8%$8.00+1,466.2%-75.6%$11.99MN/A-0.733Gap UpATHAAthira Pharma2.7364 of 5 stars$0.30+2.4%$11.25+3,625.2%-87.1%$11.79MN/A-0.1540Gap DownTRIBTrinity Biotech0.382 of 5 stars$0.65-0.3%N/A-66.9%$11.73M$61.56M-0.23480News CoverageGap UpBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownPHIOPhio Pharmaceuticals2.2118 of 5 stars$2.35+8.3%$14.00+495.7%-53.4%$11.28MN/A-0.3710EQEquillium1.8236 of 5 stars$0.32+1.7%$3.00+851.8%-50.6%$11.26M$41.10M-0.8140Gap Down Related Companies and Tools Related Companies iBio Alternatives MetaVia Alternatives Leap Therapeutics Alternatives Minerva Neurosciences Alternatives Acurx Pharmaceuticals Alternatives Athira Pharma Alternatives Trinity Biotech Alternatives Bright Green Alternatives Phio Pharmaceuticals Alternatives Equillium Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADIL) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADIL Stock Alerts